The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.
Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.
FDA developing guidelines for oncology endpoints.
Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work.
Michelle Le Beau named director of University of Chicago Cancer Research Center.
Funding opportunities listed.
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - ACOG says it will no longer accept federal funding
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025 - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
